共 50 条
- [1] Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cellsNATURE, 2024, 627 (8004) : 494 - 495Guan, XiangnanHu, RuozhenChoi, YoonhaSrivats, ShyamNabet, Barzin Y.Silva, JohnMcginnis, LisaHendricks, RobertNutsch, KatherineBanta, Karl L.Duong, EllenDunkle, AlexisChang, Patrick S.Han, Chia-JungMittman, StephanieMolden, NandiniDaggumati, PallaviConnolly, WendyJohnson, MelissaAbreu, Delvys RodriguezCho, Byoung ChulItaliano, AntoineGil-Bazo, IgnacioFelip, EnriquetaMellman, IraMariathasan, SanjeevShames, David S.Meng, RaymondChiang, Eugene Y.Johnston, Robert J.Patil, Namrata S.
- [2] Anti-TIGIT antibody tiragolumab improves PD-L1 blockade via myeloid and Treg cellsJOURNAL OF IMMUNOLOGY, 2024, 212 (01):Guan, XiangnanHu, RuozhenChoi, YoonhaSrivats, ShyamNabet, BarzinSilva, JohnMcginnis, LisaHendricks, RobertNutsch, KatherineBanta, KarlDuong, EllenDunkle, AlexisChang, PatrickHan, JoyMittman, StephanieMolden, NandiniDaggumati, Pallavi
- [3] Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells (vol 627, pg 646, 2024)NATURE, 2024, : E1 - E1Guan, XiangnanHu, RuozhenChoi, YoonhaSrivats, ShyamNabet, Barzin Y.Silva, JohnMcginnis, LisaHendricks, RobertNutsch, KatherineBanta, Karl L.Duong, EllenDunkle, AlexisChang, Patrick S.Han, Chia-JungMittman, StephanieMolden, NandiniDaggumati, PallaviConnolly, WendyJohnson, MelissaAbreu, Delvys RodriguezCho, Byoung ChulItaliano, AntoineGil-Bazo, IgnacioFelip, EnriquetaMellman, IraMariathasan, SanjeevShames, David S.Meng, RaymondChiang, Eugene Y.Johnston, Robert J.Patil, Namrata S.
- [4] Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells (vol 627, pg 646, 2024)NATURE, 2024, 630 (8016) : E9 - E9Guan, XiangnanHu, RuozhenChoi, YoonhaSrivats, ShyamNabet, Barzin Y.Silva, JohnMcginnis, LisaHendricks, RobertNutsch, KatherineBanta, Karl L.Duong, EllenDunkle, AlexisChang, Patrick S.Han, Chia-JungMittman, StephanieMolden, NandiniDaggumati, PallaviConnolly, WendyJohnson, MelissaAbreu, Delvys RodriguezCho, Byoung ChulItaliano, AntoineGil-Bazo, IgnacioFelip, EnriquetaMellman, IraMariathasan, SanjeevShames, David S.Meng, RaymondChiang, Eugene Y.Johnston, Robert J.Patil, Namrata S.
- [5] Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells (Feb, 10.1038/s41586-024-07121-9, 2024)NATURE, 2024, 627 (8005) : E11 - E11Guan, XiangnanHu, RuozhenChoi, YoonhaSrivats, ShyamNabet, Barzin Y.Silva, JohnMcGinnis, LisaHendricks, RobertNutsch, KatherineBanta, Karl L.Duong, EllenDunkle, AlexisChang, Patrick S.Han, Chia-JungMittman, StephanieMolden, NandiniDaggumati, PallaviConnolly, WendyJohnson, MelissaAbreu, Delvys RodriguezCho, Byoung ChulItaliano, AntoineGil-Bazo, IgnacioFelip, EnriquetaMellman, IraMariathasan, SanjeevShames, David S.Meng, RaymondChiang, Eugene Y.Johnston, Robert J.Patil, Namrata S.
- [6] Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockadeCANCER RESEARCH, 2023, 83 (07)Patil, Namrata S.Srivats, ShyamChoi, YoonhaGuan, XiangnanNabet, BarzinMcGinnis, LisaChiang, EugeneDunkle, AlexisO'Gorman, BillChang, Patrick S.Hu, RuozhenSilva, JohnHan, JoyAu-Yeung, AmeliaTakahashi, ChikaraMolden, NandiniDaggumati, PallaviConnolly, WendyJohnson, MelissaAbreu, Delvys RodriguezCho, Byoung ChulItaliano, AntoineGil-Bazo, IgnacioFelip, EnriquetaMellman, IraMeng, RaymondMariathasan, SanjeevJohnston, RobertShames, David S.
- [7] ANTI-TIGIT ANTIBODY TIRAGOLUMAB LEVERAGES MYELOID CELLS AND REGULATORY T CELLS TO IMPROVE PD-L1 CHECKPOINT BLOCKADEJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A495 - A495Patil, NamrataMeng, RaymondJohnston, RobertChang, PatrickSrivats, ShyamChoi, YoonhaGuan, XiangnanNabet, BarzinMcGinnis, LisaChiang, EugenePham, ThinhDunkle, AlexisO'Gorman, BillMellman, IraHu, RuozhenSilva, JohnHan, JoyAu-Yeung, AmeliaTakahashi, ChikaraMolden, NandiniDaggumati, PallaviConnolly, WendyJohnson, MelissaRodriguez Abreu, DelvysCho, Byoung ChulItaliano, AntoineGil Bazo, IgnacioFelip, EnriquetaMariathasan, SanjeevBais, CarlosShames, David
- [8] Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLCANNALS OF ONCOLOGY, 2020, 31 : S887 - S887Ahn, M-J.Niu, J.Kim, D-W.Rasco, D.Mileham, K. F.Chung, H. C.Vaishampayan, U. N.Maurice-Dror, C.Lo Russo, P.Golan, T.Chartash, E.Chen, D.Healy, J.Rajasagi, M.Lee, D. H.